BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Cancer ZEN-3694 BET bromodomain proteins Metastatic castration-resistant prostate cancer (CRPC) Phase I $40.9 Eastern Capital; NGN BioMed Opportunity II...
BioCentury | Oct 3, 2016
Financial News

Noxxon completes private placement

...Private placement Raised: EUR2.8 million ($3.2 million) Shares: 132,079 Shares after offering: 2.1 million Investors: NGN BioMed Opportunity II...
Items per page:
1 - 2 of 2
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...Cancer ZEN-3694 BET bromodomain proteins Metastatic castration-resistant prostate cancer (CRPC) Phase I $40.9 Eastern Capital; NGN BioMed Opportunity II...
BioCentury | Oct 3, 2016
Financial News

Noxxon completes private placement

...Private placement Raised: EUR2.8 million ($3.2 million) Shares: 132,079 Shares after offering: 2.1 million Investors: NGN BioMed Opportunity II...
Items per page:
1 - 2 of 2